Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

65.95 -0.12 (-0.18%)
Official Closing Price Updated: 4:15 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers
From AstraZeneca
Via Business Wire
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants
 
Via Benzinga
Benzinga Before The Bell: Kohl's Deal Talks Cancellation, Tesla's Racial Discrimination Lawsuit, Nio's Strong June Deliveries And Other Top Financial Stories Friday, July 1
CNBC Why Kohl’s Shares Are Plunging Today 
Via Benzinga
Short Volatility Alert: AstraZeneca PLC
On Tuesday, shares of AstraZeneca PLC (NASDAQ: AZN) experienced volatile short activity. After the activity, the stock price went up 2.85% to $62.83. The overall sentiment... 
Via Benzinga
Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca's COVID-19 Vaccine
 
Via Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
AstraZeneca Says Imfinzi/Chemo Combo Shows Promising Action In Late-Stage Lung Cancer Study
 
Via Benzinga
IMFINZI® (durvalumab) Plus Chemotherapy Significantly Improved Pathologic Complete Response in AEGEAN Phase III Trial in Resectable Non-Small Cell Lung Cancer
From AstraZeneca Pharmaceuticals
Via Business Wire
7 Beaten-Down S&P 500 Stocks to Buy Before They Rebound
With the market becoming more convinced that a "soft landing" is in the cards, there are many good, beaten-down S&P 500 stocks to buy. 
Via InvestorPlace
Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News
AKBA stock is up big, but the lack of news is concerning considering that Akebia Therapeutics already faces a regulatory setback. 
Via InvestorPlace
AstraZeneca Whale Trades For June 29
Someone with a lot of money to spend has taken a bearish stance on AstraZeneca (NASDAQ:AZN). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
 
Via Benzinga
Week In Review: InvoX, A Sino Biopharma Company, To Pay $161 Million To Acquire F-Star
InvoX Pharma, a Sino Biopharma subsidiary, will pay $161 million to acquire F-Star, a clinical stage company developing bispecific drugs for immunotherapies. Meanwhile, Reistone Biopharma completed a... 
Via Talk Markets
What Are Whales Doing With AstraZeneca
Someone with a lot of money to spend has taken a bearish stance on AstraZeneca (NASDAQ:AZN). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
AstraZeneca's ALXN1840 Shows Promising Action Against Copper Metabolism Disorder
 
Via Benzinga
ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community
From Alexion
Via Business Wire
Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money
With an economic hurricane on the horizon, investors are searching for alternative investment paths and profitable places to invest in. 
Via InvestorPlace
7 Blue-Chip Stocks to Buy and Hold for the Long-Haul
Blue-chip stocks that are worth accumulating in the market correction. Undervalued blue-chip stocks with robust cash flows. 
Via InvestorPlace
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
AstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial
 
Via Benzinga
PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st-line Metastatic Castration-resistant Prostate Cancer Published in New England Journal of Medicine Evidence
From AstraZeneca
Via Business Wire
Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
From AstraZeneca
Via Business Wire
Dow Jones Erased Gains Late in the Day, as Investors Continued to Consider Fears About Sluggish Economic Is Growth.
For the third week in a row, the S&P 500 lost the most ground of any of the three major 
Via Best Stocks
Topics Stocks
Exposures US Equities
Why Mereo BioPharma Shares Are Jumping Today
 
Via Benzinga
Dow Jones Today: Investors Flee The Markets On The Belief That The Federal Reserve Would Choose For The First Three-quarter Point Hike
There have been exceptions to the rule when interest rates climb quickly. Federal Reserve officials will meet on Tuesday to 
Via Best Stocks
Topics Economy Stocks
Exposures Interest Rates US Equities
Teladoc Can’t Rely On Hype To Attract Investors
Investors should think twice before buying TDOC stock, considering the negative impact of the stay-at-home phase ending. 
Via InvestorPlace
We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit
The conversation around obesity is changing. Two diabetes drug makers are at the forefront. 
Via Investor's Business Daily
5 Cathie Wood Stocks to Buy in June
These are the five best Cathie Wood stocks to buy in June. EXAS, IONS, KTOS, TRMB, and PATH can make excellent investments. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.